Live feed06:45:00·1660dPRReleasevia QuantisnowCodiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation CohortsByQuantisnow·Wall Street's wire, on your screen.CDAK· Codiak BioSciences Inc.Health Care
